Keywords: Cancer, Radiomics
Motivation: High expression of serum AFP (>400 ng/mL) in HCC patients predicts poor prognosis.
Goal(s): Identify AFP-high HCC patients who are responsive to regorafenib.
Approach: We developed a combined clinical-imaging-radiomics model to identify risk in AFP-high HCC patients post-surgery. Identify molecular differences between different risk groups through enrichment analysis and single-cell sequencing.Finally, validate the model using regorafenib treatment outcomes.
Results: The model stratified patients into high- and low-risk groups with significant OS differences (P < 0.001). Enrichment analysis showed PI3K-AKT pathway upregulation. Among 26 patients treated with regorafenib, the DCR was 61.5% in the low-risk group and 30.8% in the high-risk group.
Impact: The combined model based on clinical, imaging, and radiomics data can predict the postoperative survival status of patients. This model allows for the identification of a subgroup of patients who are at relatively low risk and responsive to regorafenib treatment.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords